AB0707 Comparative effectiveness of secukinumab and golimumab in ankylosing spondylitis assessed by matching-adjusted indirect comparison using pivotal phase 3 clinical trial data

• Published in: Annals of the rheumatic diseases Vol. 76; no. Suppl 2; p. 1301
• Main Authors: Maksymowych, W, Choy, E, Yazici, Y, Walsh, J, Thom, H, Kalyvas, C, Fox, T, Gandhi, K, Jugl, S
• Format: Journal Article
• Language: English
• Published: London BMJ Publishing Group LTD 01.06.2017
• Subjects: Ankylosing spondylitis; Clinical trials; Monoclonal antibodies; Patients; Sensitivity analysis; Spondylitis; TNF inhibitors

BackgroundNo data are available from head-to-head RCTs between secukinumab 150 mg (SEC; an anti-IL-17A) and golimumab 50 mg (GOL; a TNFi) in patients with active ankylosing spondylitis (AS). Matching-Adjusted Indirect Comparison (MAIC) can be used to estimate comparative effectiveness and enables tr...